SRPT•benzinga•
Sarepta Issues Update From Clinical Programs Focused On LGMD Subtypes 2C/R5, 2D/R3, And 2E/R4; FDA Confirmed That Screening, Dosing May Proceed In Study SRP-9005-101 For Lgmd2C/R5
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 15, 2025 by benzinga